Xenoport
Santa Clara
About Xenoport
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 251 – 500
- Total funding: $143.8M
- Funding stage: M&A
- Last round: Post-IPO Equity (Nov 2012)
- Ticker: nasdaq:XNPT
- Website: xenoport.com
- Phone: 14086167210
Industries & Categories
Biotechnology, Developer Platform, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/xenoport-3001977 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.